[Benign myocardial uptake of 99mTc-HMDP in prostate carcinoma: based on three cases].
We present three cases of patients with prostate carcinoma who underwent total body bone scintigraphy with 99mTc-Hydroxymethylene diphosphonate (99mTc-HMDP), showing myocardial uptake. Complementary diagnostic examinations were performed in these patients: cardiac (electrocardiogram and echocardiography), analysis of plasma electrolytes, including calcium, review of personal background of each patient to rule out associated disease which could have produced this uptake. No evidence of associated disease was found, processes such as heart disease, amyloidosis, hyperparathyroidism, previous chemotherapy or radiotherapy being rule out. Thus, we conclude that the myocardial uptake was secondary to the prostate carcinoma.
Poblete García
V M
VM
Unidad de Medicina Nuclear, Hospital Ntra Sra de Alarcos, Ciudad Real, Spain.
Rodado Marina
S
S
García Vicente
A
A
Soriano Castrejón
A
A
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000556:secondary*; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D006801:Humans; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D019275:Radiopharmaceuticals; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D013669:Technetium Tc 99m Medronate